Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of America Securities maintained a Hold rating on the stock and has a $32.60 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
David Li has given his Hold rating due to a combination of factors including Zai Lab’s recent financial performance and future projections. The company reported a slight decrease in quarterly revenue, although it still showed year-over-year growth. This mixed financial outcome, alongside increased research and development expenses due to upfront payments, suggests a cautious outlook.
Moreover, while Zai Lab’s gross profit margin has improved, the net loss forecast has been adjusted upwards, indicating potential challenges ahead. The company’s pipeline development is progressing, with new products entering clinical trials, which provides some optimism. However, the slowdown in growth of core products tempers this positive outlook, leading to a balanced Hold rating.
According to TipRanks, Li is ranked #7496 out of 9472 analysts.